Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Explains it best.

<< Previous

Bullboard Posts

Next >>

Comment by AngelaLon Mar 04, 2021 11:29am

102 Views

Post# 32715157

RE:Explains it best.

I am not familiar with the company's past but there is a strong record of accomplishment and achievement for their main technology, R-107. The drug has shown excellent benefit in large animal models of acute lung injury (PR from last summer) and has completed a full battery of required preclinical studies (PR last summer) and is now about to enter Phase 1 clinical trials. The Comp has wisely refocused its energy on a world-class technology targeting the Covid pandemic. I will not be surprised if we hear soon of clinical trial start and further progress.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec